Trupanion에 대한 매도 수량은 투자자에게 Trupanion의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Trupanion (NASDAQ:TRUP) 주식, 공매도 수량 보고

Trupanion

Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue primarily from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.

Trading Ideas

BARK

CHWY

FRPT

LMND

PETS

TRUP

WOOF

투자자 라이언 코헨(Ryan Cohen)은 애완동물 용품 및 애완동물 건강 제품의 성장 추세에 맞춰 2011년에 츄이(NYSE:CHWY)를 설립했다. 새로운 데이터에 따르면 코헨은 애완동물 용품 및 애완동물 보험에 대한 지출이 크게 증가하는 등 이러한 추세에 초기에 대처했을 수 있었다. 일부는 벌써 그를 전설적인 투자자(GOAT, greatest of all time)들 중 한 명으로 보고 있다. 

라이언 코헨은 GOAT? 츄이의 창립은 애완동물 용품 분야에서 엄청난 추세를 미리 예상

Trupanion Inc

WIIM

ALLY

ARES

Bakkt Holdings, Inc. Class A Common Stock

BKKT

CMTG

DAVE

ERIE

HLNE

HOOD

KNSL

KSPI

QFIN

SCHW

SEIC

SOFI

STEP

TIGR

UPST

Shares of financial companies are trading lower amid overall market weakness following the Fed's rate decision to cut rates by 25 basis points.

Northland Capital Markets analyst Greg Gibas maintains Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) with a Market Perform and raises the price target from $45 to $50.

News

Price Target

Analyst Ratings

Northland Capital Markets Maintains Market Perform on Trupanion, Raises Price Target to $50

Piper Sandler analyst John Barnidge maintains Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) with a Neutral and raises the price target from $45 to $57.

Piper Sandler Maintains Neutral on Trupanion, Raises Price Target to $57

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) sees Q4 sales of $333.000 million-338.000 million vs $329.28 million estimate.

Guidance

Trupanion Sees Q4 Sales $333.000M-338.000M vs $329.28M Est.

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) raises FY2024 sales outlook from $1.26 billion-1.28 billion to $1.28 billion-1.29 billion.

Trupanion Raises FY2024 Sales Guidance from $1.26B-1.28B to $1.28B-1.29B.

Trupanion shares are trading lower. The company reported Q3 financial results.

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.06) by 150 percent. This is a 130 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $327.456 million which beat the analyst consensus estimate of $321.803 million by 1.76 percent. This is a 14.55 percent increase over sales of $285.853 million the same period last year.

Earnings

Earnings Beats

Trupanion Q3 2024 GAAP EPS $0.03 Beats $(0.06) Estimate, Sales $327.456M Beat $321.803M Estimate

Piper Sandler analyst John Barnidge maintains Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) with a Neutral and raises the price target from $38 to $45.

Piper Sandler Maintains Neutral on Trupanion, Raises Price Target to $45

On Friday, the SEC <a target="_blank" href="https://www.sec.gov/enforcement-litigation/administrative-proceedings/34-101202-s" rel="noreferrer noopener">disclosed settling charges</a> against Austin Kauh of Wilton, CT, for insider trading before the December 2021 announcement that Kauh&#8217;s employer, Chewy, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) collaborated with Trupanion, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>).
According to the SEC&#8217;s order, Kauh was part of Chewy&#8217;s due diligence team during the period leading up to the announcement.
In this role, he learned about plans for a partnership that would allow Trupanion to offer an exclusive suite of pet health insurance and wellness plans to more than 20 million Chewy customers.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/insights/news/24/09/41068853/adobe-chair-and-ceo-sold-13-04m-in-company-stock" rel="noreferrer noopener">Adobe Chair and CEO Sold $13.04M In Company Stock</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30124615/newplot-1-8.png" alt="" class="wp-image-572907" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30124615/newplot-1-8.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30124615/newplot-1-8-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Between June 10, 2021, and August 25, 2021, Kauh purchased Trupanion stock using this material nonpublic information in violation of his duties to his employer.&nbsp;
Kauh conducted this trading in his personal account and in an account held in the name of another person.&nbsp;
When Trupanion&#8217;s stock price rose by 39% following the announcement, Kauh generated ill-gotten gains of $4,344 in his account and $12,093 in the other.&nbsp;
The SEC&#8217;s order finds that Kauh violated the SEC&#8217;s antifraud provisions.&nbsp;
Without admitting or denying the SEC&#8217;s findings, Kauh consented to the issuance of a cease-and-desist order and a five-year bar from acting as an officer or director of a public company and agreed to pay disgorgement of $4,344, prejudgment interest of $634.79, and a civil penalty of $30,297.14.
Chewy stock is up over 57% in the last 12 months. Trupanion&nbsp;stock is up over 57%.
Price Action: CHWY stock is down 2.34% at $29.27 at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/insights/news/24/09/41096486/insider-decision-scott-robinson-exercises-options-at-donaldson-for-1-57m" target="_blank" rel="noreferrer noopener">Insider Decision: Scott Robinson Exercises Options At Donaldson For $1.57M</a></li>
</ul>
Photo via Shutterstock.

Government

Regulations

Insider Trades

Chewy Insider Penalized by SEC for Trading on Confidential Pet Insurance Deal Info

Stifel analyst Jonathan Block maintains Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) with a Hold and raises the price target from $30 to $40.

Stifel Maintains Hold on Trupanion, Raises Price Target to $40

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $39.0, a high estimate of $56.00, and a low estimate of $30.00. Marking an increase of 25.81%, the current average surpasses the previous average price target of $31.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1726837243_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Trupanion among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Greg Gibas</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Greg Gibas</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Trupanion. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Trupanion compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Trupanion's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Trupanion's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TRUP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Trupanion analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Trupanion</h2>
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue primarily from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.
<h3>Trupanion's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Trupanion's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 16.35%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Trupanion's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -1.86%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -1.92%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Trupanion's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.74%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Trupanion's debt-to-equity ratio is below the industry average at 0.42, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 6 Analyst Insights On Trupanion

B of A Securities analyst Joshua Shanker maintains Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) with a Buy and raises the price target from $47 to $56.

B of A Securities Maintains Buy on Trupanion, Raises Price Target to $56

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Trupanion and provided 12-month price targets. The average target is $35.6, accompanied by a high estimate of $45.00 and a low estimate of $30.00. Observing a 28.06% increase, the current average has risen from the previous average price target of $27.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1726771569_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Trupanion among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Gibas</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Greg Gibas</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Trupanion. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Trupanion compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Trupanion's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Trupanion's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TRUP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Trupanion analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Trupanion Better</h2>
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue primarily from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.
<h3>Trupanion: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Trupanion's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 16.35%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Trupanion's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1.86%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Trupanion's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.92%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Trupanion's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.74%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Trupanion's debt-to-equity ratio is below the industry average. With a ratio of 0.42, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Have This To Say About Trupanion

Northland Capital Markets analyst Greg Gibas maintains Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) with a Market Perform and raises the price target from $35 to $45.

Northland Capital Markets Maintains Market Perform on Trupanion, Raises Price Target to $45

Trupanion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>), the leading global provider of medical insurance for cats and dogs, announced today the official launch of its high-quality Trupanion product in Germany and Switzerland. The launch follows the Company's expansion to Continental Europe in 2022 with the acquisition of two rapidly growing pet insurance companies with strong expertise in the region. &nbsp;

Global

Trupanion Announces The Official Launch Of Its High-Quality Trupanion Product In Germany And Switzerland

<ul>
<li>Boehringer Ingelheim, Mars Science &amp; Diagnostics and leading pet, public health and animal health authorities to join Advisory Board&nbsp;</li>
<li>Collaboration to address emerging pet and public health threats&nbsp;to protect pets and people
<ul>
<li>Early detection potential has global pet and public health benefits&nbsp;</li>
</ul>
</li>
</ul>

Trupanion Partners With CDC And Leading Pet Industry Partners To Launch Pet & Public Health Early Warning & Detection System

Northland Capital Markets analyst Greg Gibas maintains Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) with a Market Perform and raises the price target from $30 to $35.

Northland Capital Markets Maintains Market Perform on Trupanion, Raises Price Target to $35

Piper Sandler analyst John Barnidge maintains Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) with a Neutral and raises the price target from $30 to $38.

Piper Sandler Maintains Neutral on Trupanion, Raises Price Target to $38

Stifel analyst Jonathan Block reiterates Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) with a Hold and raises the price target from $22 to $30.

Reiteration

Stifel Reiterates Hold on Trupanion, Raises Price Target to $30

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.18) by 22.22 percent. The company reported quarterly sales of $314.800 million which beat the analyst consensus estimate of $309.326 million by 1.77 percent. This is a 16.35 percent increase over sales of $270.566 million the same period last year.

Trupanion Q2 2024 GAAP EPS $(0.14) Beats $(0.18) Estimate, Sales $314.800M Beat $309.326M Estimate

Northland analyst Greg Gibas raised the firm's price target on Trupanion (TRUP) to $50 from $45 and keeps a Market Perform rating on the shares aft...

Trupanion price target raised to $50 from $45 at Northland

In a report released yesterday, Jonathan Block from Stifel Nicolaus maintained a Hold rating on Trupanion (TRUP – Research Report), with a price ta...

Stifel Nicolaus Keeps Their Hold Rating on Trupanion (TRUP)

Sezzle, Upstart, Coinbase lead week's financial movers with huge gains

Meeting to be held on November 14 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...

Trupanion management to meet with Piper Sandler

Piper Sandler analyst John Barnidge assigned a Hold rating to Trupanion (TRUP – Research Report) today and set a price target of $57.00. The compan...

Trupanion (TRUP) Gets a Hold from Piper Sandler

Trupanion (TRUP) would like to thank a 9-year-old Maltipoo from Coral Springs, Florida named Lexi for helping the Seattle based company achieve a m...

Trupanion reports paying over $3B in medical bills to veterinarians, pet parents

Trupanion: High Costs And Price Hikes Are Reasons To Avoid This Pet Insurer

Financials allocations top all-time high – BofA's Global FMS

Analysts fell to the sidelines weighing in on Flushing Financial (FFIC – Research Report) and Trupanion (TRUP – Research Report) with neutral ratin...

Comments

Trupanion

매도 수량

Trupanion (NASDAQ:TRUP) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌